Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management
Thomas Chow,
William Humble,
Enrico Lucarelli,
Carmine Onofrillo,
Peter F. Choong,
Claudia Di Bella,
Serena Duchi
Affiliations
Thomas Chow
Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia; BioFab3D-ACMD, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
William Humble
BioFab3D-ACMD, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Department of Surgery, The University of Melbourne, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
Enrico Lucarelli
Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy
Carmine Onofrillo
BioFab3D-ACMD, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Department of Surgery, The University of Melbourne, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
Peter F. Choong
BioFab3D-ACMD, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Department of Surgery, The University of Melbourne, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
Claudia Di Bella
BioFab3D-ACMD, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Department of Surgery, The University of Melbourne, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Department of Orthopaedics, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
Serena Duchi
BioFab3D-ACMD, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Department of Surgery, The University of Melbourne, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; Corresponding author
Summary: Osteosarcoma is a highly aggressive primary bone tumor that has seen little improvement in survival rates in the past three decades. Preclinical studies are conducted on a small pool of commercial cell lines which may not fully reflect the genetic heterogeneity of this complex cancer, potentially hindering translatability of in vitro results. Developing a single-site laboratory protocol to rapidly establish patient-derived primary cancer cell lines (PCCL) within a clinically actionable time frame of a few weeks will have significant scientific and clinical ramifications. These PCCL can widen the pool of available cell lines for study while patient-specific data could derive therapeutic correlation. This endeavor is exceedingly challenging considering the proposed time constraints. By proposing key definitions and a clear theoretical framework, this evaluation of osteosarcoma cell line establishment methodology over the past three decades assesses feasibility by identifying barriers and suggesting solutions, thereby facilitating systematic experimentation and optimization.
